The molecular understanding of PFK isoform selectivity, coupled with future studies of the pyrazolo-oxazepine scaffold, could open the door to selective activation of PFKM and PFKP, and the development of new pharmacological therapies for diabetes and cancer. This evidence concerns the gene PFKM and diabetes mellitus.